Chugai Pharmaceutical Co Ltd (4519) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Published : Dec-2017

No. of Pages : 106

order by fax Inquire before Buying request discount

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11
Chugai Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 13
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 17
Partnerships 17
Helsinn Enters into Licensing Agreement with Chugai Pharma for Netupitant-Palonosetron Fixed-Dose Combination 17
Chugai Pharma Enters into Research Agreement with National Cancer Center Japan 18
Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 19
Chugai Pharmaceutical Enters into Agreement with Osaka University 21
Chugai Pharma Enters Into Co-Development Agreement With Nippon Shinyaku For GA101 22
Schnell BioPharma Enters Into Co-Development Agreement With Aprogen And Chunggei Pharm 23
Licensing Agreements 24
JW Pharma Enters into Licensing Agreement with Chugai Pharma 24
Chugai Pharma Enters into Licensing Agreement with SBI Pharma 25
Chugai Pharma Enters into Licensing Agreement with Pharma Mar 26
Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 27
Roche Enters into Licensing Agreement with Chugai Pharma for Recycling Antibody SA237 28
Chugai Pharma Enters into Licensing Agreement with Two Cells 29
BioMarin Pharma Enters into Sub-license Agreement with Chugai Pharma 30
PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 31
Chugai Pharma Enters into Licensing Agreement with Roche 32
Maruho Enters into Licensing Agreement with Chugai Pharma 33
Galderma Pharma to Enter into Licensing Agreement with Chugai Pharma 34
Kowa Company Enters into Licensing Agreement with Chugai Pharmaceutical 35
EpiVax Enters into Licensing Agreement with Chugai Pharma 36
Roche Amends Licensing Agreement with Chugai Pharma 37
Helsinn Enters Into Licensing Agreement With Chugai Pharma Marketing For Anamorelin 38
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 39
Chugai Pharma Expands Licensing Agreement with Kowa for DEBERZA 40
Chugai Pharma Extends Licensing Agreement With Genedata For Genedata Expressionist Software 41
Chugai Pharma Enters Into Licensing Agreement With Roche For MetMAb And Lebrikizumab 42
Chugai Pharma Enters Into Licensing Agreement With Roche For Vemurafenib 43
Asset Transactions 44
Taiyo Pharma to Acquire Product Rights from Chugai Pharma and Roche 44
Eisai Acquires Rights to Manufacture Active Pharmaceutical Ingredients in Japan from Chugai Pharma and F. Hoffman-La Roche 45
Acquisition 46
Roche May Acquire 40% Stake in Chugai Pharma 46
Chugai Pharmaceutical Co Ltd - Key Competitors 47
Chugai Pharmaceutical Co Ltd - Key Employees 48
Chugai Pharmaceutical Co Ltd - Locations And Subsidiaries 50
Head Office 50
Other Locations & Subsidiaries 50
Joint Venture 52
Recent Developments 53
Strategy And Business Planning 53
Jan 27, 2017: Aiming to Provide Solutions that Meet Changes of Regional Healthcare Services 53
Government and Public Interest 54
Mar 30, 2017: Chugai - ASTAR Joint Development Project for Anti-Dengue Virus Antibody Selected as Grant Recipient by the GHIT Fund 54
Product News 55
12/15/2016: Roche Receives CHMP Positive Opinion for Alecensa 55
12/01/2016: Tocilizumab to be listed on Australian Pharmaceutical Benefits Scheme 56
11/30/2016: Filing for Approval of "Actemra" for Additional Indication of "Large Vessel Vasculitis," the Designated Intractable Disease 57
10/31/2016: Health Canada approves ALECENSARO - a targeted oral treatment - for patients with aggressive and rare form of lung cancer 58
10/13/2017: CHMP recommends EU approval of Roche's Alecensa (alectinib) as a first-line treatment for people with ALK-positive NSCLC 60
10/04/2016: US FDA grants Breakthrough Therapy Designation for Roche's Alecensa (alectinib) for first-line treatment of people with ALK-positive NSCLC 61
10/04/2016: FDA Grants Breakthrough Therapy Designation for Genentech's Actemra (Tocilizumab) in Giant Cell Arteritis, a Form of Vasculitis 63
08/31/2016: ACTEMRA Subcutaneous Injection Wins a Prize at the JAPAN PACKAGING CONTEST 2016 65
08/10/2017: Announcement of Commencement of Arbitration against Chugai 66
06/26/2017: Approval of Additional Dosage for "Actemra Subcutaneous Injection" Reducing Dose Interval to One Week in Patients with Rheumatoid Arthritis Who Inadequately Respond to Bi-weekly Dose 67
05/22/2017: FDA approves first drug to specifically treat giant cell arteritis 68
04/04/2017: NICE Terminates Appraisal for Alectinib in Previously Treated ALK-positive Advanced NSCLC 69
02/27/2017: Chugai's ALK Inhibitor "Alecensa" Approved in Taiwan 70
02/21/2017: Roche receives EU approval of Alecensa (alectinib) for people with previously treated ALK-positive non-small cell lung cancer 71
01/06/2016: NIHR: New treatment approach for Pulmonary Arterial Hypertension being tested 73
Product Approvals 74
Sep 01, 2017: Roche and MHRA to make treatment available for those newly diagnosed with a rare type of lung cancer in the UK before anywhere else in Europe 74
May 08, 2017: Roche's Alecensa Rejects For Use Within NHS Scotland 75
Jan 23, 2017: FDA Grants Priority Review For Genentech's Actemra (Tocilizumab) Supplemental Biologics License Application For Giant Cell Arteritis, a Form of Vasculitis 76
Aug 25, 2016: Application for Approval of Additional Dosage for "Actemra Subcutaneous Injection" in Patients with Rheumatoid Arthritis Who Inadequately Respond to Every Other Week Dosage 77
Mar 17, 2016: Chugai receives Orphan Drug Designation for Tocilizumab in Systemic Scleroderma 78
Clinical Trials 79
Sep 06, 2017: Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer 79
Aug 09, 2017: Genentech Completes Phase III Enrollment for Study of Actemra in Systemic Sclerosis 80
Aug 02, 2017: FDA Grants Genentech's Alecensa Priority Review for Initial Treatment of People with ALK-Positive Lung Cancer 81
Jul 26, 2017: Positive Phase III Results of Genentech's Actemra (Tocilizumab) for the Treatment of Giant Cell Arteritis Published in New England Journal of Medicine 83
Jul 21, 2017: Roche Gains Positive CHMP Opinion for Actemra / Roactemra in Giant Cell Arteritis 85
Jun 06, 2017: Alectinib potential new standard of care for ALK-positive non-small lung cancer 86
Jun 05, 2017: Phase III study showed Roche's Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer 87
May 11, 2017: Results of the J-ALEX Study for Chugais Alecensa are Published in The Lancet Online 89
Apr 10, 2017: Phase III study shows Roche's Alecensa was superior to crizotinib in a specific type of lung cancer 90
Apr 03, 2017: Phase III ALUR study supports the use of Roche's Alecensa for people with advanced ALK-positive lung cancer 91
Mar 02, 2017: Chugai's Anti-IL-31 Receptor A Humanized Monoclonal Antibody "nemolizumab (CIM331)" Global Phase II Study Data Published in The New England Journal of Medicine Online 93
Feb 08, 2017: Roche's Alecensa (alectinib) approved in Switzerland for people with a specific type of lung cancer 94
Nov 12, 2016: Phase III GiACTA study shows Roches Actemra/RoActemra is superior to steroids alone in maintaining steroid-free remission for people with giant cell arteritis 96
Nov 02, 2016: Roche to present new data on Actemra/RoActemra at the 2016 ACR/ARHP Annual Meeting 98
Jun 06, 2016: Phase III study shows Roche's Actemra/RoActemra maintained steroid-free remission in people with Giant Cell Arteritis (GCA) 100
May 18, 2016: Phase III Study of Genentech's Alecensa (Alectinib) Showed Superior Efficacy Versus Crizotinib in Japanese People With a Specific Type of Lung Cancer 101
May 16, 2016: Efficacy of Actemra Subcutaneous Injection Confirmed in Dose Interval Reduction Study in Patients with Rheumatoid Arthritis Who Inadequately Respond to Bi-weekly Dose 102
Mar 05, 2016: Chugai Announces Phase II Global Study Results of Nemolizumab (CIM331) in Late-breaking Research Forums at AAD 103
Feb 10, 2016: Chugai ALK Inhibitor Alecensa Trial Stopped Early for Benefit 104
Other Significant Developments 105
Apr 04, 2017: A First Approach in the Japanese Pharmaceutical Industry Starting a Trial of a Drug Adherence Support App Using Multidisciplinary SNS for Outpatient Cancer Treatment 105
Appendix 106
Methodology 106
About GlobalData 106
Contact Us 106
Disclaimer 106

List of Tables
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Chugai Pharmaceutical Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 11
Chugai Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 13
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
Helsinn Enters into Licensing Agreement with Chugai Pharma for Netupitant-Palonosetron Fixed-Dose Combination 17
Chugai Pharma Enters into Research Agreement with National Cancer Center Japan 18
Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 19
Chugai Pharmaceutical Enters into Agreement with Osaka University 21
Chugai Pharma Enters Into Co-Development Agreement With Nippon Shinyaku For GA101 22
Schnell BioPharma Enters Into Co-Development Agreement With Aprogen And Chunggei Pharm 23
JW Pharma Enters into Licensing Agreement with Chugai Pharma 24
Chugai Pharma Enters into Licensing Agreement with SBI Pharma 25
Chugai Pharma Enters into Licensing Agreement with Pharma Mar 26
Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 27
Roche Enters into Licensing Agreement with Chugai Pharma for Recycling Antibody SA237 28
Chugai Pharma Enters into Licensing Agreement with Two Cells 29
BioMarin Pharma Enters into Sub-license Agreement with Chugai Pharma 30
PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 31
Chugai Pharma Enters into Licensing Agreement with Roche 32
Maruho Enters into Licensing Agreement with Chugai Pharma 33
Galderma Pharma to Enter into Licensing Agreement with Chugai Pharma 34
Kowa Company Enters into Licensing Agreement with Chugai Pharmaceutical 35
EpiVax Enters into Licensing Agreement with Chugai Pharma 36
Roche Amends Licensing Agreement with Chugai Pharma 37
Helsinn Enters Into Licensing Agreement With Chugai Pharma Marketing For Anamorelin 38
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 39
Chugai Pharma Expands Licensing Agreement with Kowa for DEBERZA 40
Chugai Pharma Extends Licensing Agreement With Genedata For Genedata Expressionist Software 41
Chugai Pharma Enters Into Licensing Agreement With Roche For MetMAb And Lebrikizumab 42
Chugai Pharma Enters Into Licensing Agreement With Roche For Vemurafenib 43
Taiyo Pharma to Acquire Product Rights from Chugai Pharma and Roche 44
Eisai Acquires Rights to Manufacture Active Pharmaceutical Ingredients in Japan from Chugai Pharma and F. Hoffman-La Roche 45
Roche May Acquire 40% Stake in Chugai Pharma 46
Chugai Pharmaceutical Co Ltd, Key Competitors 47
Chugai Pharmaceutical Co Ltd, Key Employees 48
Chugai Pharmaceutical Co Ltd, Other Locations 50
Chugai Pharmaceutical Co Ltd, Subsidiaries 51
Chugai Pharmaceutical Co Ltd, Joint Venture 52

List of Figures
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 9
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11
Chugai Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 13

Filed in: Pharmaceutical

Publisher : GlobalData

Name:
Email:
Phone:
Subject:
Comments:

More Reports

Title	Price	Buy Now
Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027 “The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......	$4950
Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027 “The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......	$
Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027 “Digital Pharmacy market to register a CAGR of 17.0% during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated to grow at the highest rate during the forecast period” On the basis ofdrug type, t......	$4950
Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027 The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......	$4950
Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027 The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases, growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders, rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on product in 2021.” Based on products, the topical drug delivery the market is segmented into ......	$4950
Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026 “Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......	$4950
High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027 The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......	$4950
Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027 “Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......	$4950
Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027 “Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......	$4950
Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027 The global Healthcare cloud computing market is projected to reach USD 89.4 billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......	$4950

Chugai Pharmaceutical Co Ltd (4519) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Benefits of Sandler Research

User License for Reports

Reach Us

Contact Us

Knowledge Store

Email Subscription

our Feed Reader

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027